|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 嵌体和高嵌体粘结修复的循证理念及治疗要点第一部分:一种生物替代治疗的历史回顾及其临床合理性显示文摘本系列文章的第一部分主要探讨后牙间接粘结性修复的最新理论和技术以及有关这方面的最佳科学研究和长期临床证据。本文提出的治疗理念基于以下几个基本思想:①使用粘结性材料垫底/衬洞[“双重粘结”技术(DB).“最优化窝洞设计”(CDO)]:必要时使用②龈下颈部边缘的即刻重建[龈壁提升(CMR)]:随后进行③印模制取.以尽量保留牙体组织.简化临床操作.最后使用高填料光固化复合树脂材料进行粘结[粘结层固化可控化(CAC)]。并简要介绍修复体就位的辅助技术.如声波/超声波震动和(或)粘结材料加热技术。文中介绍的临床步骤有助于牙医解决嵌体/高嵌体牙色修复中的诸多临床问题,包括牙体预备、隔湿、取印模和粘结等每一个关键步骤。此种临床步骤既适用于全瓷修复材料.也适用于复合树脂.从理化性能和操作性方面来看.目前尚未有任何一种材料被证实可以胜任任何临床情形的修复。虽然嵌体/高嵌体的粘结修复并不是完美的牙釉质一牙本质结构的复制品,但就目前来讲,我们还是将这种间接修复方式视为一种生物替代性修复,主要归因于该修复体的均质材料性质。 | Didier Dietschi Roberto Spreafico 何利邦 甄理 段晓磊 袁鹤 | 2016 | 中国口腔医学继续教育杂志2016，0，6： | 4 |
| 2 | Transarterial chemoembolization using 40 μm drug eluting beads for hepatocellular carcinoma显示文摘AIM To assess the safety and efficacy of transarterial chemoembolization(TACE) of hepatocellular carcinoma(HCC) using a new generation of 40 μm drug eluting beads in patients not eligible for curative treatment.METHODS Drug eluting bead TACE(DEB-TACE) using a new generation of microspheres(embozene tandem,40 μm) preloaded with 100 mg of doxorubicin was performed on 48 early or intermediate HCC patients with compensatedcirrhosis.Response to therapy was assessed with Response Evaluation Criteria in Solid Tumors(RECIST) and modified RECIST(m RECIST) guidelines applied to computed tomography or magnetic resonance imaging.Eleven out of the 48 treated patients treated progressed on to receive liver orthotopic transplantation(OLT).This allowed for histological analysis on the treated explanted nodules.RESULTS DEB-TACE with 40 μm showed a good safety profile without major complications or 30-d mortality.The objective response rate of treated tumors was 72.6% and 26.7% according to m RECIST and RECIST respectively.Histological examination in 11 patients assigned to OLT showed a necrosis degree > 90% in 78.6% of cases.The overall time to progression was 13 mo(11-21).CONCLUSION DEB-TACE with 40 μm particles is an effective treatment for the treatment of HCC in early-intermediate patients(Barcelona Clinic Liver Cancer stage A/B) with a good safety profile and good results in term of objective response rate and necrosis. | Giorgio Greco Tommaso Cascella Antonio Facciorusso Roberto Nani Rodolfo Lanocita Carlo Morosi Marta Vaiani Giuseppina Calareso Francesca G Greco Antonio Ragnanese Marco A Bongini Alfonso V Marchianò Vincenzo Mazzaferro Carlo Spreafico | 2017 | World Journal of Radiology2017，9，5： | 3 |
| 3 | Radiofrequency Ablation of Small Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation: A Prospective Study显示文摘 | Vincenzo Mazzaferro Carlo Battiston Stefano Perrone Andrea Pulvirenti Enrico Regalia Raffaele Romito Dario Sarli Marcello Schiavo Francesco Garbagnati Alfonso Marchianò Carlo Spreafico Tiziana Camerini Luigi Mariani Rosalba Miceli Salvatore Andreola | 2004 | Annals of Surgery2004，，5： | 3 |
| 4 | Transarterial Chemoembolization for Hepatocellular Carcinoma with a New Generation of Beads: Clinical–Radiological Outcomes and Safety Profile显示文摘 | Carlo Spreafico Tommaso Cascella Antonio Facciorusso Carlo Sposito Lanocita Rodolfo Carlo Morosi Enrico M. Civelli Marta Vaiani Sherrie Bhoori Alessandro Pellegrinelli Alfonso Marchianò Vincenzo Mazzaferro | 2015 | CardioVascular and Interventional Radiology2015，，1： | 2 |
| 5 | Yttrium‐90 radioembolization for intermediate‐advanced hepatocellular carcinoma: A phase 2 study显示文摘 | Vincenzo Mazzaferro Carlo Sposito Sherrie Bhoori Raffaele Romito Carlo Chiesa Carlo Morosi Marco Maccauro Alfonso Marchianò Marco Bongini Rodolfo Lanocita Enrico Civelli Emilio Bombardieri Tiziana Camerini Carlo Spreafico | 2013 | Hepatology2013，，： | 2 |
| 6 | Long-term results of suppressing thyroid-stimulating hormone during radiotherapy to prevent primary hypothyroidism in medulloblastoma/PNET and Hodgkin lymphoma:a prospective cohort study显示文摘Primary hypothyroidism commonly occurs after radiotherapy(RT),and coincides with increased circulating thyroid-stimulating hormone(TSH)levels.We tested therefore the protective effect of suppressing TSH with L-thyroxine during RT for medulloblastoma/PNET and Hodgkin lymphoma(HL)in a prospective cohort study.From 1998 to 2001,a total of 37 euthyroid children with medulloblastoma/PNET plus 14 with HL,scheduled for craniospinal irradiation and mediastinum/neck radiotherapy,respectively,underwent thyroid ultrasound and free triiodothyronine(FT3),free thyroxine(FT4),and TSH evaluation at the beginning and end of craniospinal iiradiation.From 14 days before and up to the end of radiotherapy,patients were administered L-thyroxine checking every 3 days TSH to ensure a value<0.3μIU/mL.During follow-up,blood tests and ultrasound were repeated;primary hypothyroidism was considered an increased TSH level greater than normal range.Twenty-two/37 patients with medulloblastoma/PNET and all the 14 patients with HL were alive after a median 231 months from radiotherapy with 7/22 and 8/14 having correctly reached TSH levels˂0.3μIU/mL and well matched for other variables.Twenty years on,hypothyroidism-free survival rates differed significantly,being 60%±15%and 15.6%±8.2%in TSH-suppressed vs.not-TSH suppressed patients,respectively(P=0.001).These findings suggest that hypothyroidism could be durably prevented in two populations at risk of late RT sequelae,but it should be confirmed in a larger cohort. | Maura Massimino Marta Podda Lorenza Gandola Emanuele Pignoli Ettore Seregni Carlo Morosi Filippo Spreafico Andrea Ferrari Emilia Pecori Monica Terenziani | 2021 | Frontiers of Medicine2021，15，1： | 2 |
| 7 | GABA-A receptor impairment in the genetic absence epilepsy rats from strabourg ( GAERS ): an immunocytochemical and receptor binding autoradiographic study 显示文摘 | Spreafico R Mennini T Danober L | 1993 | Epilepsy Res1993，15，3： | 1 |
| 8 | CYP2C9 genotypes and does requirements during the induction phase of oral anticogulant therapy显示文摘 | PEYVANDI F SPREAFICO M SIBONI S M | 2004 | Clin Pharmacol Ther2004，75，3： | 1 |
| 9 | Damage, reorganization,and abnormal neocortical hyperexcitability in the pilocarpine model of temporal lobe epilepsy显示文摘 | Sanabria ER da Silva AV Spreafico R | 2002 | Epilepsia2002，43，5： | 1 |
| 10 | Endodermal sinus tumor of the vagina显示文摘 | Terenziani M Spreafico F Collini P | 2007 | Pediatr Blood Cancer2007，48，5： | 1 |
| 11 | Analysis of the International Classification of Headache Disorders for diagnosis of migraine and tension-type headache in children显示文摘 | VAJANI Stefania CORTINOVIS Ivan SPREAFICO Federica | 2008 | Dev Med Child Neurol2008，50，4： | 1 |
| 12 | CT- guided percutaneous cryoablation of renal masses in selected patients 显示文摘 | Spreafico C Nicolai N Lanocita R | 2012 | Radiol Med2012，117，4： | 1 |
| 13 | Uric acid-driven Thl7 differentiation requires inflammasome-derived IL-1 and IL-18显示文摘 | Conforti-Andreoni C Spreafico R Qian HL | 2011 | J Immunol2011，187，11： | 1 |
| 14 | Rasrnussen's encepha- litis: early characleristics allow diagnosis 显示文摘 | Granata T Gobbi G Spreafico R | 2003 | Neurology2003，60，3： | 1 |
| 15 | Semen characteristics and inflam- matory mediators in infertile men with different clinical diagnoses显示文摘 | Moretti E Cosci I Spreafico A | 2008 | IntJ Androl2008，8，1： | 1 |
| 16 | Zinc salt catalyzed rearrangement of acetals of opticauy active aryl l-chloroethyl ketohes:Synthesis of Optically Active 2-Arylpropionic Acids显示文摘 | Piccolo O Spreafico F Visentin G | 1987 | J Ory Chem1987，5210，： | 1 |
| 17 | Osteogenic growth peptide effects on primary human osteoblast cultures; potential relevance for the treatment of glucocorticoid-induced osteoporosis显示文摘 | Spreafico A Frediani B Capperucci C | 2006 | J Cell Biochem2006，98，4： | 1 |
| 18 | Malignant peripheral nerve sheath tumors in children:a single-institution twenty-year experience显示文摘 | Casanova M Ferrari A Spreafico F | 1999 | J Pediatr Hematol Oncol1999，21，6： | 1 |
| 19 | Dosing anticoagulant therapy with coumarin drugs: is genotypingclinically useful? No显示文摘 | MANNUCCI PM SPREAFICO M PEYVANDI F | 2008 | J Thromb Haemost2008，9，1： | 1 |
| 20 | Sur,r:val of a- dults treated for medulloblastoma using pediatric protocols 显示文摘 | Spreafico F Massimino M Gandola L | 2005 | Eur J Cancer2005，41，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员